Cargando…

Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Jianjun, He, Qiuming, Subudhi, Sumit, Aparicio, Ana, Zurita-Saavedra, Amado, Lee, Da Hyun, Jimenez, Camilo, Suarez-Almazor, Maria, Sharma, Padmanee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530091/ https://www.ncbi.nlm.nih.gov/pubmed/25659583 http://dx.doi.org/10.1038/onc.2015.5

Ejemplares similares

Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
por: Hahn, Andrew W., et al.
Publicado: (2023)

Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer
por: Subudhi, Sumit K, et al.
Publicado: (2015)

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
por: Bilen, Mehmet Asim, et al.
Publicado: (2016)

Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project
por: Edwards, Beatrice J., et al.
Publicado: (2017)

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center
por: Vo, Henry Hiep, et al.
Publicado: (2022)

M.D. Anderson, Oncología /
Publicado: (2000)

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
por: Siddiqui, Bilal A, et al.
Publicado: (2021)

Neoadjuvant treatment: the MD Anderson experience
por: Hortobagyi, GN
Publicado: (2005)

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022)

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
por: Sinha, Meenal, et al.
Publicado: (2021)

M.D. Anderson Cancer Center, oncología quirúrgica /
Publicado: (2005)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

ETMR-04. EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES: THE MD ANDERSON CANCER CENTER EXPERIENCE
por: Gupta, Sumit, et al.
Publicado: (2020)

Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience
por: Barber, Fedricker D., et al.
Publicado: (2022)

Obituary Notice of Thomas Anderson, M.D., F.L.S.
Publicado: (1870)

EPEN-10. SPINAL MYXOPAPILLARY EPENDYMOMA AND METHYLATION-PROFILING: THE MD ANDERSON CANCER CENTER (MDACC) EXPERIENCE
por: Gupta, Sumit, et al.
Publicado: (2020)

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience
por: Conter, Henry J., et al.
Publicado: (2014)

Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience
por: El Hussein, Siba, et al.
Publicado: (2020)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
por: Abdel-Wahab, Noha, et al.
Publicado: (2016)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

The Pioneer of Women Practitioners: Elizabeth Garrett Anderson, M.D. Paris, L.S.A.
Publicado: (1917)

LPTO-09. INTRATHECAL TOPOTECAN FOR LEPTOMENINGEAL METASTASIS IN SOLID TUMORS: THE MD ANDERSON EXPERIENCE
por: Sinicrope, Kaylyn D, et al.
Publicado: (2019)

A longitudinal study of the Swedish MD Anderson Dysphagia Inventory in patients with oral cancer
por: Tuomi, Lisa, et al.
Publicado: (2020)

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Psychometric Properties of MD Anderson Symptoms Inventory for Acute Myeloid Leukemia Patients in Thailand
por: Rattanathammethee, Thanawat, et al.
Publicado: (2022)

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
por: Jabbour, Elias, et al.
Publicado: (2023)

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
por: Garcia, Christine A., et al.
Publicado: (2018)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Making Cancer History: Disease and Discovery at the University of Texas M.D. Anderson Cancer Center
por: Hyland, Callen
Publicado: (2010)

Validity and Reliability of the Korean Version of the MD Anderson Dysphagia Inventory for Head and Neck Cancer Patients
por: Kwon, Chan-Hyuk, et al.
Publicado: (2013)

DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes
por: Kuerer, Henry M., et al.
Publicado: (2017)

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience
por: Tarek, Nidale, et al.
Publicado: (2020)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

Evolution in Surgical Management of Breast Cancer-related Lymphedema: The MD Anderson Cancer Center Experience
por: Chang, Edward I., et al.
Publicado: (2020)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ar4a87r5fiehl9rk9bd4s8p38i